CANNABIS CULTURE – California marijuana activist Steve Kubby and growing guru and publisher Ed Rosenthal have announced plans to produce high-CBD cannabis medicine products through their new company called KUSH Inc.
CC recently spoke with Kubby and Rosenthal about the duo’s new joint-venture:
Cannabis Culture: Where are you getting the cannabinoids and terpines that will go in your products from?
Ed Rosenthal: The terpenes are legal products that are sold without restriction. They are used in the food and fragrance industries and are available from the refiners and manufacturers.
CC: Are you getting any of the constituents from legal Colorado hemp?
Steve Kubby: We will have to wait and see about Colorado, but whatever we do, we won’t be violating US federal law. Our Board of Directors includes former Governor Gary Johnson, former US Senator Mike Gravel, jurist James P. Gray and former LAPD Deputy Chief Steven Downing, so we are fortunate to have a management team that is well-versed in US federal drug laws and policies.
CC: What products are you going to be creating? What are the medical constituents of cannabis that will be the active ingredients in these products?
Steve Kubby: Our initial focus will be on non-psychoactive CBD products that still provide powerful relief for inflammation and pain. However, we have aggressive projects in several other countries to produce potent THC-rich lozenges.
Ed Rosenthal: We will be producing both intermediate and retail products. Intermediate products are infused syrups used by other manufacturers to manufacture infused edibles. We have many choices of retail products we will produce; edibles, drinks, lozenges, even gum.
CC: Can you provide links and/or sources to some of the most convincing research that went into your decision to select certain cannabinoids and terpenes for use in medical products?
Ed Rosenthal: There are many papers on CBD available online so most of the information about it is readily available. The US government was granted a patent on it for controlling inflammation. We are using it for different purposes. Information on terpenes can be extrapolated from published plant odor research. We used both inductive and deductive matrixes as well as a series of mind experiments that popularized by early 20th century scientists. We have found this an efficient method, since proof of theory can be verified using targeted lab work.
CC: Could you comment on the relationship between intellectual property rights and botanical medicines?
Steve Kubby: We believe the future is in developing privately-owned strains to provide unique medical or psychoactive benefits, not in patents or even trademarks, since those are controlled by a government that is still fiercely anti-cannabis.
Ed Rosenthal: We are also interested in developing customized remedies based either on symptoms or disease. This entails use of combinations of natural ingredients which optimize treatment paradigms. This work as well as development of various varieties will remain proprietary.
CC: What’s the difference between a “proprietary strain” and a “patent”?
Steve Kubby: “Proprietary strain” simply means our own strains that we have created and that we reserve for our own products. We are actually pioneering the opposite of a patent or biopiracy. I’ve spent eight years breeding a strain that has a unique psychoactive high that is motivational and anti-fatigue. I haven’t patented the strain or the type of high created by it. Nobody else is prevented from attempting to reproduce and benefit from my research.
CC: What are your views about the future of cannabis medicine, once all the medically active elements have been researched fully?
Steve Kubby: Heating or even drying cannabis destroys powerful cannabinoids, so future meds will rely upon cold temperature extraction of whole live plants.
Ed Rosenthal: Since endogenous cannabinoids have been used in life forms as simple as sea urchins, that is non-vertabrates, and has been preserved in vertabrates up to humans, you could extrapolate that it is pretty important to life. It is involved in retrograde signaling, that is regulation the nervous system as well as cell metabolism. This gives cannabinoid medicines the keys required to affect our bodies and minds.
CC: What size of market are we talking about with regards to your current and future range of products, and what are your projections regarding what percentage of this market you could reasonably expect to claim for yourself, including any market expansion you predict may result from cannabis medicine products becoming more well-known and more widely accessible?
Steve Kubby: We hope to earn a dominant market share of what we believe is a trillion dollar emerging industry.
CC: Do you have any plans to fund California legalization initiatives with some of the profits of your KUSH venture?
Steve Kubby: What do you think first got me thinking about making money with KUSH? After all, I live a pretty nice life already as a Tahoe ski bum, so I don’t have much need for more money in my life. Maybe I just got tired of begging rich guys for their money to fund these critical initiatives.
CC : If people are interested in either carrying your products or working with you or investing with you, whom should they talk to?
Steve Kubby: I suggest they go to our website at KUSHcorporate.com. They can also contact me personally, at [email protected]. KUSH is in an acquisition mode right now. We are seeking strategic partners who can create synergistic relationships with us. For example, we’d like to find a distribution company with $1-10M in revenue. We have investors who will put up $1-3M on the increase in equity created by merging two companies like this. That means cash to take both companies to the next level. We are also interested in acquiring skin care and cosmetic companies to help us cover the demand for hemp-based CBD-rich creams and salves. We’ve just signed a contract with Hemp Inc to distribute our products and we’re scrambling to cover all the new orders. Despite all this sudden growth, KUSH is committed to remaining debt-free and focused on fundamentals such as building equity, earning trust from our customers and stockholders, delivering superior products and giving back to the community.
Cannabis Culture also contacted David Tobias, head of Hemp Inc., and asked him:
CC: Would you please tell us a little bit about, Hemp Inc., your plans to distribute KUSH products, and your vision of the future of cannabis-based medicines?
David Tobias: Hemp Inc. has a vision to change the world for the better. The hemp plant has a myriad of uses that are hand in hand with sustainability and enviornmental stewardship. We realize that to instigate industrial change requires institutional financing. To that end, we are working to educate through our portal of Hemp.com, which will be undergoing a dramatic reconstructing this year. Part of that effort will be a revamped marketplace for consumers to find all things hemp. Divisions of Hemp Inc. include the Herbagenix line of nutracueticals that are formulated in-house, an entertainment and educational division, Marijuana Inc. and a software/rewards program, Eco-Harmony Inc.
Find out more about KUSH products.